PLEASE JOIN US AT THE 2022 ASCO ANNUAL CONFERENCE

Are you getting the full story?

9 Posters – New Data – Take our poll and we’ll donate


PLEASE JOIN US AT THE 2022 ASCO ANNUAL CONFERENCE

Are you getting the full story?

9 Posters – New Data – Take our poll and we’ll donate


Cast your VOTE and we’ll DONATE!

We are donating $10 to the Susan G. Komen Foundation for each poll completed so visit Agendia’s 2022 ASCO booth.

AGENDIA AT THE 2022 ASCO ANNUAL CONFERENCE

Agendia will present new data from ongoing clinical research evaluating the combination of MammaPrint and BluePrint genomic tests. The Data will highlight Agendia’s clinical focus on whole transcriptome analysis as well as breast cancer care for underserved populations, in addition to several sub-studies derived from the company’s FLEX Trial, the real-world, multicenter, prospective, observational breast cancer study. Two abstracts selected by ASCO for oral discussion will feature an investigation of the ImPrint genomic test, currently for research use only, from the I-SPY trial series and an analysis from FLEX of hormone receptor-positive breast cancer in Black women classified by BluePrint.

We invite you to meet our team via live chat. We can discuss genomic testing in the pre-operative setting, or answer any questions you might have.

Poster Spotlights

Agendia will be showcasing 9 posters during this years annual oncology conference. Click here to see all posters and sessions.

Booth Information

Booth Number #19143
Please visit our booth and take our poll to help us donate to the Susan G. Komen Foundation.

Visit Agendia’s at Booth #19143

Visit our booth for more information and to speak with a member of our team.

Agendia’s Presentations and Posters

ORAL PRESENTATION

The ImPrint immune signature identifies high risk early breast cancer patients who may benefit from PD1 checkpoint inhibition in I-SPY2

Speaker: Kuilman, MM., et al.
Session Type: Oral Abstract Session
Date: Monday, June 6, 2022
Abstract: #514

ORAL PRESENTATION

Whole transcriptomic analysis of HR+ breast cancer in Black women classified as basal-type by BluePrint

Speaker: Reid, S., et al.
Session Type: Oral Abstract Session
Date: Monday, June 6, 2022
Abstract: #517

POSTER PRESENTATION

Defining transcriptomic profiles of early-stage mucinous breast cancers: A FLEX sub study

Speaker: Sivapiragasam, A., et al.
Session Type: Oral Abstract Session
Date: Sunday, June 5, 2022
Abstract: #3134

POSTER PRESENTATION

Whole transcriptome analysis of tumors with discordant oncotype and MammaPrint results in the FLEX trial

Speaker: Socoteanu, M., et al.
Session Type: Oral Abstract Session
Date: Monday, June 6, 2022
Abstract: #556

Clinical implications for patients with discordant Oncotype and MammaPrint results

Speaker: Socoteanu, M., et al.
Session Type: Oral Abstract Session
Date: Monday, June 6, 2022
Abstract: #560

POSTER PRESENTATION

Investigation of a genomic signature for transcription factor MAF gene amplification and lack of bisphosphonate benefit in early breast cancer

Speaker: Nasrazadani, A., et al.
Session Type: Oral Abstract Session
Date: Monday, June 6, 2022
Abstract: #559

POSTER PRESENTATION

Identification of transcriptional changes with MammaPrint and BluePrint in early-stage breast cancer after neoadjuvant chemotherapy

Speaker: Chung, A., et al.
Session Type: Oral Abstract Session
Date: Monday, June 6, 2022
Abstract: #585

POSTER PRESENTATION

Distribution of breast cancer molecular subtypes within receptor classifications: Lessons from the I-SPY2 Trial and FLEX Registry

Speaker: Cha, J., et al.
Session Type: Oral Abstract Session
Date: Monday, June 6, 2022
Abstract: #592

POSTER PRESENTATION

FLEX, the 30,000 breast cancer transcriptome project: A platform for early breast cancer research using full-genome arrays paired with clinical data

Speaker: Ma, C., et al.
Session Type: Oral Abstract Session
Date: Monday, June 6, 2022
Abstract: #612

Have Questions? Contact Us Today.

  • This field is for validation purposes and should be left unchanged.

FOR PROVEN RESULTS

Trusted by leading physicians and institutions around the world

Genomic Testing Cell Photo

Landmark Trials

Data on the validation and utility of MammaPrint and BluePrint for patients with early stage breast cancer.

Two women reading about genomic breast cancer results

Latest News

Agendia Presents New Data Demonstrating MammaPrint’s Clinical Utility in Treatment Decisions for Ultra-Low Risk Breast Cancer Patients […]

Who We Are

Our purpose, our story our vision. Hear how Agendia fits into the evolving landscape of technology and cancer care.

*Not an official event of the 2022 ASCO Annual Meeting